학술논문

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL
Document Type
Article
Source
In Blood 18 February 2021 137(7):939-944
Subject
Language
ISSN
0006-4971